Quoin Pharmaceuticals Applies for Orphan Drug Designation for QRX003
Quoin Pharmaceuticals announced that following a successful meeting with the Japanese MHLW that it has submitted an application for Orphan Drug Designation, ODD, for its lead product candidate, QRX003, for the treatment of Netherton Syndrome. At the meeting, the MHLW confirmed that QRX003 qualifies for both ODD and Fast Track regulatory review in Japan. If granted, QRX003 will have ODD status in Quoin's three core commercial territories of the US, EU and Japan.
